Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EE5F | ISIN: US4037831033 | Ticker-Symbol: L9S
Tradegate
06.06.25 | 16:34
7,050 Euro
-4,73 % -0,350
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GYRE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
GYRE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,2507,50006.06.
7,3507,45006.06.

Aktuelle News zur GYRE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrGYRE THERAPEUTICS, INC. - 8-K, Current Report-
29.05.Gyre Therapeutics Inc.: Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares1
23.05.Gyre Therapeutics kündigt neue Aktienemission an5
23.05.Gyre Therapeutics slumps 16%, prices $20M stock offering1
23.05.Gyre: Phase 3 Trial Of Hydronidone In Chronic Hepatitis B Meets Main Goal; Prices $20 Mln Offering2
23.05.Gyre Therapeutics Inc.: Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock3
22.05.Gyre Therapeutics commences underwritten public offering2
22.05.Gyre Therapeutics Inc.: Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis ...91Achieved statistically significant =1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events...
► Artikel lesen
GYRE THERAPEUTICS Aktie jetzt für 0€ handeln
22.05.Gyre Therapeutics Inc.: Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock2
22.05.GYRE THERAPEUTICS, INC. - 8-K, Current Report2
09.05.GYRE THERAPEUTICS, INC. - 10-Q, Quarterly Report2
09.05.Gyre Therapeutics GAAP EPS of $0.00 misses by $0.03, revenue of $22.1M misses by $6.3M2
09.05.GYRE THERAPEUTICS, INC. Q1 Earnings Summary1
09.05.Gyre Therapeutics Inc.: Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update 128Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B ("CHB")-associated liver...
► Artikel lesen
09.05.GYRE THERAPEUTICS, INC. - 8-K, Current Report-
28.04.GYRE THERAPEUTICS, INC. - 8-K, Current Report1
27.03.Gyre Therapeutics treibt Phase-3-Studie zu Leberfibrose voran5
27.03.Gyre Therapeutics advances Phase 3 liver fibrosis trial1
20.03.GYRE THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans3
17.03.Gyre Therapeutics GAAP EPS of $0.00 misses by $0.04, revenue of $27.87M beats by $4.37M1
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1